Jefferies analyst Dennis Ding upgraded Esperion to Buy from Hold with a $12 price target as he assumed coverage of the stock, citing a better management tone into Phase 3 CLEAR CV outcomes data due at ACC on March 4 and better visibility into the company’s cash runway. The firm is "fairly confident" Esperion should meet or beat the Street’s 15% cardiovascular benefit "bar," but even if risk reduction is more modest, it thinks the totality of the data would still look attractive to doctors as an oral LDL option.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ESPR:
- Esperion Launches New Scientific Website
- CLEAR Outcomes Company Update Call: Detailed Results Discussion
- Esperion Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update
- Esperion reports Q4 EPS (76c), consensus (84c)
- Esperion Announces Positive CLEAR Outcomes Results To Be Presented as Late-Breaking Clinical Trial at ACC.23/WCC